PD-L1 and PD-L2 expression in pancreatic ductal adenocarcinoma and their correlation with immune infiltrates and DNA damage response molecules

Yue Zhang†, Xianlong Chen†, Shengwei Mo, Heng Ma, Zhaohui Lu, Shuangni Yu and Jie Chen*

Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, PR China

*Correspondence to: Jie Chen, Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 1 Shuaifuyuan, Dongcheng District, Beijing 100730, PR China. E-mail: chenjie@pumch.cn

†These authors contributed equally to this work.

Abstract

Immunotherapy targeting programmed cell death-1 (PD-1) has considerably improved the prognosis of patients with advanced cancers; however, its efficacy in the treatment of pancreatic ductal adenocarcinoma (PDAC) is unfavourable. To address the issue of PDAC immunotherapy, we investigated the expression of two PD-1 ligands, PD-L1 and PD-L2, in PDAC, analysed their role in survival, and explored their correlation with clinicopathological features, immune infiltration, and DNA damage response molecules. Immunohistochemistry was performed on 291 surgically resected PDAC samples. In tumour cells (TCs) and immune cells (ICs), the positivity of PD-L1 expression was 30 and 20% and that of PD-L2 expression was 40 and 20%, respectively. Moreover, PD-L1 expression on TCs correlated with its expression on ICs (p < 0.0001); a similar result was observed for PD-L2 (p < 0.0001). Nonetheless, no correlation was observed between PD-L1 and PD-L2 expression. Positive PD-L1 expression on TCs was related to N1 stage (p = 0.011) and AJCC II stage (p = 0.002), whereas positive PD-L2 expression on TCs was associated with high FOXP3+ cell infiltration (p = 0.001) and high BRCA2 expression (p < 0.0001). Survival analysis revealed that positive PD-L1 (p = 0.046) and PD-L2 (p = 0.028) expression on TCs was an independent risk factor for unfavourable disease-specific survival (DSS). Furthermore, positive PD-L2 expression on TCs was an independent risk factor for lower DSS in the pN0 (p = 0.023), moderate and well tumour differentiation (p = 0.004), low BRCA1 (p = 0.017), wild-type p53 (p = 0.034), and proficient mismatch repair (p = 0.004) subgroups. Moreover, post-operative adjuvant chemotherapy could significantly affect DSS, regardless of PD-L1/PD-L2 expression status (positive or negative) on TCs, while it only prolonged DSS in PD-L1-ICs (p < 0.0001) and PD-L2-ICs (p < 0.0001) subgroups. This study provides a comprehensive understanding of the roles of PD-L1 and PD-L2 in PDAC, supporting anti-PD-1 axis immunotherapy for PDAC.

Keywords: pancreatic ductal adenocarcinoma; PD-L1; PD-L2; tumour-infiltrating lymphocytes; DNA damage response

Introduction

Pancreatic ductal adenocarcinoma (PDAC) is a highly malignant tumour with a 5-year survival rate of about 8% [1]. Surgical resection is the only curative treatment; however, most patients continue to receive adjuvant chemotherapy to prevent disease recurrence. Compared with traditional chemotherapy, cancer immunotherapy has made significant progress in improving the prognosis of patients with various solid tumours such as lung cancer and melanomas [2,3]. However, the efficacy in PDAC is unfavourable [4–7].

Programmed cell death-1 (PD-1) is an immune checkpoint expressed on activated CD4+ T cells, CD8+ T cells, and peripheral B cells [8]. PD-1 regulates the immune response by inhibiting T-cell proliferation and IFN-γ production in T cells [9]. PD-1 has two ligands: PD-L1 and PD-L2. PD-L1 is widely expressed in various haematopoietic cells and tissue cells [10,11]. However, PD-L2 is expressed almost
exclusively on antigen-presenting cells and the ligand can be induced in other cells through multiple micro-environmental stimuli [12,13].

In many cases, immunotherapy targeting PD-1/PD-L1 has a substantial effect on advanced cancers. Several factors influence the response to anti-PD-1/PD-L1 therapy, such as PD-L1 expression level, tumour genomic stability, and tumour-infiltrating lymphocytes (TILs) [14]. High responders typically exhibit increased PD-L1 expression owing to the upregulation of ectopic promoters resulting from gene amplification and translocation [15,16]. Nonetheless, some PD-L1-positive patients have shown poor response to anti-PD-1 therapy, whereas a number of PD-L1-negative patients respond well, suggesting that other ligands of PD-1 such as PD-L2 may also be relevant to the efficacy of PD-1 axis immunotherapy [17,18]. One study on head and neck squamous cell carcinomas reported that response to pembrolizumab was higher in the PD-L1 and PD-L2 double positive groups than in the PD-L1 single positive group [19]. In addition, they reported that, in patients treated with pembrozumab, PD-L2 was an independent predictor of progression-free survival (PFS). Overall, these results suggested that PD-L2 should also be considered for anti-PD-1 axis therapy.

Genomic stability is maintained by DNA damage response (DDR) through multiple repair pathways including mismatch repair (MMR) and homologous recombination repair [20]. Accumulating evidence suggests that tumours with mutations in the genes responsible for genomic stability could be potential targets for PD-1/PD-L1 therapy. For example, studies on colon cancer and gastroesophageal cancer showed that patients with microsatellite instability (MSI) have a significantly higher response to anti-PD-L1 therapy [21,22]. Moreover, patients with BRCA2 mutations (a major player in homologous recombination repair) showed a high response to anti-PD-1 therapy in melanoma [23]. As a classical tumour suppressor, p53 maintains genome stability by orchestrating various DDR mechanisms [24]. Nevertheless, the correlation between p53 and PD-1 ligands has rarely been reported in PDAC.

Currently, the efficacy of anti-PD-1 axis immunotherapy in pancreatic cancer is limited and the role of PD-L2 in PDAC has been rarely reported; thus, we investigated the influence of PD-L1 and PD-L2 expression on both tumour cells (TCs) and immune cells (ICs) in resected PDAC and analysed their correlation with T (CD3+, CD4+, CD8+, FOXP3+, and CD45RO+) and B (CD20+) lymphocytes, CD15+ neutrophils and CD68+ macrophage infiltration, and several DDR molecules, including major players in homologous recombination repair (BRCA1 and BRCA2), proteins associated with MMR (MLH1, MSH2, MSH6, and PMF6), as well as p53. Moreover, the role of PD-L1 and PD-L2 in predicting PDAC survival was explored. Our study helps to provide a more comprehensive understanding of the roles of PD-L1 and PD-L2 in PDAC and support immunotherapy for PDAC.

Materials and methods

Clinical information for PDAC patients

A total of 291 patients who were diagnosed with primary PDAC and underwent surgical resection at the Peking Union Medical College Hospital between June 2015 and April 2019 were included in this study. Clinical baseline information was obtained from the electronic medical record system of the hospital. Patients who died because of post-operative complications were excluded when conducting survival analysis. None of the patients received preoperative immunotherapy, chemotherapy, or radiotherapy. The follow-up ended in October 2020. This retrospective study was approved by the Institutional Review Board of the Peking Union Medical College Hospital (approval number: S-K1593; date: 2 April 2021) and was carried out in conformity to the Declaration of Helsinki. Written informed consent was obtained from all patients.

TMA construction and immunohistochemistry

Two experienced pathologists (XC and SM) independently reviewed all the original haematoxylin and eosin (HE)-stained slides to confirm that the diagnosis was correct. Subsequently, representative tumour tissues and tumour-associated stromal areas were labelled on HE-stained slides, and tissue microarray (TMA) blocks were collected. Finally, TMA instruments were used to construct 12 × 8 (row × column) TMAs with a 2-mm core for each case (Sakura Finetek USA, Torrance, CA, USA).

For immunohistochemistry, 4-μm TMA sections were deparaffinised with xylene and rehydrated in serial concentrations of ethanol, followed by heat-induced epitope retrieval using a citrate retrieval buffer (pH 6.0) or EDTA retrieval buffer (pH 9.0) solution, as specified by the manufacturer’s protocol. The internal peroxidase activity was depleted by 3% H₂O₂, and non-specific antibody reactions were blocked with prediluted goat serum (ZLI-9056; ZSGB-BIO, Beijing, PR China). Tissue sections were incubated with primary antibodies against PD-L1, PD-L2, CD3, CD4, CD8, CD45RO, FOXP3, CD20, CD15, CD68, p53,
BRCA1, BRCA2, PMS2, MLH1, MSH2, and MSH6 at 37 °C for 1 h. Detailed antibody information is provided in supplementary material, Table S1. Negative controls were prepared without the primary antibody.

Immunostaining scoring
Evaluation of immunohistochemical (IHC) staining was conducted independently by two pathologists who were unaware of the patients’ baseline information. Both pathologists re-examined the slides and reached a consensus if there were any disagreements. The staining of PD-L1 and PD-L2 on the ICs was classified as negative or positive. For the evaluation of TCs, positive expression was defined as membranous positive labelling of ≥1% of the TCs [17,25]. For CD3, CD4, CD8, CD45RO, FOXP3, CD20, CD15, and CD68 scoring, four high-power fields with relatively abundant positive staining were selected for cell counting, and the mean value was recorded. In addition, four quartile ranges were used to set the cut-off values.

For p53 immunostaining scoring, abnormal p53 expression was defined as either positive staining in ≥50% of the TC nuclei or the complete absence of nuclear staining compared with adjacent normal tissue [26]. Normal and abnormal p53 expression was marked as wild-type (WT) p53 and mutant p53, respectively. For BRCA1 and BRCA2 evaluation, a cut-off value of 50% was used to define high (≥50% of the TCs were positively stained) and low (<50% of the TCs were positively stained) expression [27]. Loss of the MMR proteins (MLH1, MSH2, MSH6, and PMS2) expression was defined as a complete loss of nuclear expression in the TCs, whereas the internal control, including acinar, ductal, islet, and ICs, showed appropriate nuclear labelling. Thus, deficient MMR (dMMR) was defined as the loss of expression of any of the MMR proteins, whereas proficient MMR (pMMR) indicates that all the MMR proteins were expressed [28].

Next-generation sequencing
DNA was extracted from formalin-fixed paraffin-embedded tissue (Qiagen, Germantown, MD, USA) and analysed by next-generation sequencing (NGS) of the BRCA1 and BRCA2 genes. Sequencing was performed on 60 PDAC cases with the available DNA.

Statistical analysis
All statistical analyses were conducted in SPSS version 21.0 (SPSS Inc., Chicago, IL, USA). The Kaplan–Meier method was used to plot survival curves. Differences between the Kaplan–Meier curves were tested for significance by the log-rank test, and the figures were generated using GraphPad Prism 8.0 (GraphPad Software Inc., San Diego, CA, USA). Correlation analysis between PD-L1/PD-L2 and categorical variables was performed using chi-square test or Fisher’s exact test. Cox proportional hazards model (Enter method) was used for univariate analysis and variables with \( p < 0.25 \) were selected for multivariate analysis. The statistical significance was set at \( p < 0.05 \).

Results
Expression of PD-L1 and PD-L2 in PDAC
In total, 291 patients were included in this study and the median age was 61 years (range: 25–83 years). Tumour grade and stage were defined based on the eighth edition of the American Joint Committee on Cancer (AJCC). Detailed baseline information is summarised in supplementary material, Table S2. TMA cores were excluded if they were lost during immunostaining. Finally, 264 and 255 cases with intact PD-L1 and PD-L2 staining information, respectively, were selected for further analysis. PD-L1 and PD-L2 exhibited expression on both TCs and ICs; the positivity of PD-L1 and PD-L2 expression on ICs was 20% (54/264 and 50/255, respectively) and on TCs was 30% (80/264 and 50/255, respectively). We used two different antibodies for PD-L1 IHC staining and the positivity between them was strongly correlated (\( \rho = 0.977, p < 0.0001 \)). Representative images of PD-L1 and PD-L2 staining are shown in Figure 1.

Associations among PD-L1, PD-L2, and immune infiltrates
Positive PD-L1 expression on TCs was observed more frequently among the samples in which ICs were also PD-L1-positive (\( p < 0.0001 \)) (supplementary material, Table S3). The same result was also observed for PD-L2 (\( p < 0.0001 \)). However, positive expression of PD-L1 and PD-L2 on TCs was not correlated (\( p = 0.148 \)). As shown in supplementary material, Table S3, 61 of the PD-L1-negative samples (64.2%) showed positive PD-L2 staining, 38 of the PD-L2-negative samples (27.0%) were PD-L1 positive, and 34 samples exhibited co-expression of PD-L1 and PD-L2.

There was no correlation between positive expression of PD-L1 on TCs and any other immune markers (supplementary material, Table S4). Nonetheless, positive PD-L1 expression on ICs was significantly related to high CD3
(p = 0.007), CD4 (p = 0.023), CD8 (p = 0.043), FOXP3 (p < 0.0001), CD45RO (p = 0.014), and CD68 (p = 0.011) infiltration; in contrast, positive PD-L2 expression on ICs was only related to high Foxp3 (p = 0.015) infiltration (supplementary material, Table S5). In addition, positive PD-L2 expression on TCs was more frequent in the high FOXP3 expression group (p = 0.001), with 57.4% of the highest FOXP3 infiltration samples showing positive PD-L2 expression (supplementary material, Table S4). There was no correlation between CD20 and PD-L1/PD-L2. These results suggest a correlation between immune infiltration and PD-L1/ PD-L2 expression in PDAC.

Association between clinicopathological parameters, DDR molecules, and PD-L1/PD-L2

Correlation analysis showed that positive PD-L1 expression on TCs was more frequent in the N1 stage (p = 0.011) and AJCC II stage (p = 0.002) groups; however, there was no relationship between clinicopathological features and PD-L2 expression on TCs (supplementary material, Table S6). Conversely, positive PD-L2 expression on ICs was significantly associated with vascular invasion (p = 0.033) (supplementary material, Table S7). Additionally, there was no significant correlation between the expression of PD-L1/PD-L2 and post-operative liver metastasis (supplementary material, Tables S6 and S7).

IHC scoring showed that the rate of mutant p53 in our sample set was 70% (190/272) (supplementary material, Table S2), which is similar to those in previous studies [26,29]. Nonetheless, the percentage of dMMR in PDAC varies between studies and was 12% (35/291) in this study. Furthermore, NGS data revealed that the mutation rate of BRCA1 and BRCA2 in a subset of this cohort was 6.7% (4/60) and 5.0% (3/60), respectively. Besides, 5.9% (3/51) of low BRCA1 expression samples harboured BRCA1 mutation, and BRCA2 mutation was detected in 7.0% (3/43) of low BRCA2 expression samples (supplementary material, Table S8). The analysis of the correlation between PD-L2 and DDR

Figure 1. Representative images of PD-L1, PD-L2, and BRCA IHC staining. (A) Negative expression of PD-L1. (B, C) Positive expression of PD-L1 on TCs and ICs. (D) Negative expression of PD-L2. (E, F) Positive expression of PD-L2 on TCs and ICs. (G) HE staining of PDAC. (H, I) Low and high expression of BRCA1. (J, K) Low and high expression of BRCA2.
molecules revealed positive PD-L2 expression in 53.9% \( (n = 48) \) of the samples with high BRCA2 expression, and PD-L2 expression on TCs was significantly related to BRCA2 expression \( (p < 0.0001) \) (supplementary material, Table S9). However, the correlation between PD-L2 expression on ICs and BRCA2 expression was not significant \( (p = 0.115) \) (supplementary material, Table S10). Representative images of BRCA staining are shown in Figure 1. Moreover, p53 status, MMR status, and BRCA1 expression were not associated with PD-L2. In addition, there was no correlation between PD-L1 and DDR molecules (supplementary material, Tables S9 and S10). These results suggest that PD-L2 expression on TCs may be associated with DDR status.

### Table 1. Univariate analysis of DSS and PFS factors.

|                      | DSS HR (95% CI) | DSS P value | PFS HR (95% CI) | PFS P value |
|----------------------|----------------|-------------|----------------|-------------|
| Age (years)          |                |             |                |             |
| <60                  | Ref            | 0.303       | Ref            | 0.378       |
| ≥60                  | 1.172 (0.866–1.585) | <0.0001     | 1.133 (0.859–1.494) | <0.0001     |
| Differentiation (grade) |            |             |                |             |
| Moderate and well    | Ref            |             | Ref            |             |
| Poor                 | 2.035 (1.506–2.751) |             | 1.769 (1.339–2.338) |             |
| Location             |                |             |                |             |
| Head                 | Ref            | 0.004       | Ref            | 0.001       |
| Body and tail        | 0.632 (0.460–0.867) |             | 0.603 (0.451–0.807) |             |
| Perineural invasion  |                |             |                |             |
| No                   | Ref            | 0.409       | Ref            | 0.351       |
| Yes                  | 1.145 (0.830–1.579) |             | 1.151 (0.856–1.548) |             |
| Vascular invasion    |                |             |                |             |
| No                   | Ref            | 0.214       | Ref            | 0.127       |
| Yes                  | 1.213 (0.895–1.646) |             | 1.243 (0.940–1.645) |             |
| T stage              |                |             |                |             |
| T1 and T2            | Ref            | 0.001       | Ref            | 0.002       |
| T3 and T4            | 1.749 (1.266–2.418) |             | 1.603 (1.182–2.173) |             |
| N stage              |                |             |                |             |
| N0 and N1            | Ref            | 0.002       | Ref            | 0.002       |
| N2                   | 1.806 (1.249–2.612) |             | 1.762 (1.241–2.501) |             |
| AJCC stage           |                |             |                |             |
| I and II             | Ref            | <0.0001     | Ref            | <0.0001     |
| III and IV           | 2.134 (1.522–2.992) |             | 2.022 (1.466–2.788) |             |
| PD-L1 on TCs         |                |             |                |             |
| Negative             | Ref            | 0.014       | Ref            | 0.039       |
| Positive             | 1.511 (1.087–2.100) |             | 1.319 (1.017–1.870) |             |
| PD-L1 on ICs         |                |             |                |             |
| Negative             | Ref            | 0.515       | Ref            | 0.889       |
| Positive             | 1.131 (0.781–1.636) |             | 1.025 (0.725–1.449) |             |
| PD-L2 on TCs         |                |             |                |             |
| Negative             | Ref            | 0.038       | Ref            | 0.065       |
| Positive             | 1.404 (1.039–1.934) |             | 1.320 (0.983–1.773) |             |
| PD-L2 on ICs         |                |             |                |             |
| Negative             | Ref            | 0.202       | Ref            | 0.085       |
| Positive             | 1.290 (0.873–1.907) |             | 1.367 (0.958–1.951) |             |
| p53 status           |                |             |                |             |
| Mutant               | Ref            | 0.127       | Ref            | 0.092       |
| WT                   | 1.311 (0.926–1.856) |             | 1.312 (0.956–1.801) |             |
| MMR status           |                |             |                |             |
| pMMR                 | Ref            | 0.109       | Ref            | 0.078       |
| dMMR                 | 0.663 (0.401–1.097) |             | 0.659 (0.414–1.049) |             |
| BRCA1                |                |             |                |             |
| Low expression       | Ref            | 0.474       | Ref            | 0.644       |
| High expression      | 0.832 (0.503–1.376) |             | 0.899 (0.571–1.413) |             |
| BRCA2                |                |             |                |             |
| Low expression       | Ref            | 0.796       | Ref            | 0.948       |
| High expression      | 0.958 (0.690–1.329) |             | 1.010 (0.754–1.353) |             |
Survival analysis of PDAC

Univariate analysis indicated that poor differentiation \((p < 0.0001)\), tumour location at the head of the pancreas \((p = 0.004)\), T3–T4 stage \((p = 0.001)\), N2 stage \((p = 0.002)\), AJCC III–IV stage \((p < 0.0001)\), and positive PD-L1 \((p = 0.014)\) and PD-L2 \((p = 0.038)\) expression on TCs were associated with low disease-specific survival (DSS) of PDAC (Table 1). Furthermore, multivariate analysis indicated that poor tumour differentiation (hazard ratio [HR]: 1.799, 95% confidence interval [CI]: 1.275–2.537, \(p = 0.001\)), AJCC III and IV stage (HR: 2.353, 95% CI: 1.601–3.459, \(p < 0.0001\)), and positive expression of PD-L2 on TCs \((p = 0.028)\) (Tables 1 and 2). Kaplan–Meier survival curves for PD-L1 and PD-L2 are shown in Figure 2.

In addition, survival analysis for immune infiltrates showed that high CD3\(^+\) \((p = 0.016)\), CD4\(^+\) \((p = 0.034)\), and CD20\(^+\) \((p = 0.018)\) lymphocyte infiltration was associated with a favourable DSS. Conversely, high CD15\(^+\) neutrophil infiltration was related to poor DSS \((p = 0.014)\), FOXP3\(^+\) and CD8\(^+\) lymphocyte infiltration was not significant for predicting patients’ DSS; however, high FOXP3\(^+\) lymphocyte infiltration was related to poor PFS \((p = 0.046)\) (supplementary material, Figures S1 and S2).

Modification of PD-L2 by clinicopathological features and DDR molecule subgroups

It is possible that PD-L2 can be modified by several important clinicopathological features and DDR molecules. Therefore, the stratification of PD-L2 expression on TCs by lymph node status, grade, AJCC stage, BRCA1, BRCA2, p53, and MMR status was assessed to determine a prognostic value of DSS for the various subgroups. No statistical significance was observed when PD-L2 was stratified by AJCC stage and BRCA2 (Table 3). However, multivariate analysis revealed that positive expression of PD-L2 on TCs was an independent prognostic factor for lower DSS in patients with pN0 stage (HR: 2.044, 95% CI: 1.105–3.780, \(p = 0.023\)), moderate and well tumour differentiation (HR: 1.965, 95% CI: 1.249–3.092, \(p = 0.004\)), low BRCA1 expression (HR: 1.523, 95% CI: 1.078–2.152, \(p = 0.017\)), WT p53 status (HR: 2.220, 95% CI: 1.061–4.647, \(p = 0.034\)), and pMMR status (HR: 1.692, 95% CI: 1.178–2.432, \(p = 0.004\)) (Table 3). Kaplan–Meier survival curves of PD-L2 expression on TCs stratified by different subgroups are shown in Figure 3 and supplementary material, Figure S3.

Table 2. Multivariate analysis of DSS and PFS factors.

| Location                  | DSS HR (95% CI) | P value | PFS HR (95% CI) | P value |
|---------------------------|-----------------|---------|-----------------|---------|
| Head                      | Ref             | 0.001   | Ref             | 0.048   |
| Body and tail             |                 |         |                 |         |
| Differentiation (grade)   |                 |         |                 |         |
| Poor                      | 1.799 (1.275–2.537) | <0.0001 | 1.571 (1.146–2.155) | <0.0001 |
| Moderate and well         | Ref             |         | Ref             |         |
| AJCC stage                |                 |         |                 |         |
| I and II                  | Ref             |         | Ref             |         |
| III and IV                | 2.353 (1.601–3.459) |         | 1.966 (1.374–2.813) |         |
| PD-L1 on TCs              |                 |         |                 |         |
| Positive                  | 1.403 (1.010–2.055) |         |                 |         |
| Negative                  | Ref             |         | Ref             |         |
| PD-L2 on TCs              |                 |         |                 |         |
| Positive                  | 1.476 (1.042–2.091) |         |                 |         |
| Negative                  | Ref             |         | Ref             |         |

Associations among PD-L1, PD-L2, and chemotherapy efficacy

The relationship between PD-1 ligands and the efficacy of post-operative adjuvant chemotherapy was scarcely reported in PDAC. In our cohort, 193 (66.3%) patients received post-operative adjuvant chemotherapy. The median DSS in the PDL1-TCs\(^{(-)}\) and PDL1-TCs\(^{(+)}\) groups were 18.77 and 16.30 months, respectively, and adjuvant chemotherapy was significantly related to a better DSS in both groups \((p = 0.008\) and \(p < 0.0001\), respectively), suggesting that the expression of PD-L1 on TCs would not affect the efficacy of adjuvant chemotherapy. However, adjuvant chemotherapy was
statistically associated with a favourable DSS ($p < 0.0001$) in the PDL1-ICs$(-)$ group, which was not observed in the PDL1-ICs$($+)$ group ($p = 0.061$). A similar result was also found for PD-L2 (supplementary material, Figure S4). These results suggest that the expression of PD-1 ligands on ICs, but not on TCs, may be associated with post-operative adjuvant chemotherapy efficacy.

**Discussion**

Although numerous clinical trials have shown favourable outcomes of PD-1/PD-L1 immunotherapy in the treatment of various tumours, their efficacy in PDAC is limited [4–7]. Unlike PD-L1, PD-L2 has been less studied in PDAC, but the role of PD-L2 in...
predicting patient survival and PD-1 axis therapy efficacy should not be neglected. To overcome the bottleneck associated with PD-1 axis immunotherapy and increase the understanding of the role of the two PD-1 ligands in predicting the survival of PDAC patients, we analysed whether the combination of PD-L1/PD-L2 and tumour-infiltrating T lymphocytes as well as molecules associated with genomic stability could indicate post-operative survival in PDAC.

We evaluated PD-L1 and PD-L2 expression on TCs and ICs separately. PD-L1 positivity was 30 and 20% and PD-L2 positivity was 40 and 20% on TCs and ICs, respectively. Furthermore, our results showed that 61 of the PD-L1-negative samples (64.2%) were PD-L2-positive, 38 of the PD-L2-negative samples (27%) showed PD-L1 staining, and 34 samples co-expressed PD-L1 and PD-L2. However, none of our patients received anti-PD-1 axis therapy; thus, we could not analyse the correlation between the single or double expression of the two PD-1 ligands and anti-PD-1 immunotherapy efficacy. Future studies exploring immunotherapy efficacy in PDAC should focus on analysing this correlation. For the survival analysis, a positive PD-L1 (HR: 1.511, 95% CI: 1.087–2.100, \( p = 0.014 \)) or PD-L2 (HR: 1.404, 95% CI: 1.039–1.934, \( p = 0.038 \)) expression on TCs was associated with a lower DSS in PDAC, which was consistent with the findings of previous studies [30,31].

TILs are important factors affecting survival in PDAC. Our study showed that high CD3\(^+\), CD4\(^+\), and CD20\(^+\) cell infiltration was associated with better DSS, whereas high CD15\(^+\) cell infiltration was related to poor DSS, which was consistent with previous studies [32–34]. Besides, high FOXP3\(^+\) cell infiltration was related to poor PFS possibly due to the immune suppression mediated by FOXP3\(^+\) T regulatory cells. Moreover, TILs could also associate with the outcomes of PD-1/PD-L1 therapy. One study using a tumour immune microenvironment model reported that PD-L1 and TIL double positive tumours showed a relatively high response to PD-1/PD-L1 blockade therapy, whereas PD-L1 single positive tumours were prone to resistant to PD-1/PD-L1 inhibitor monotherapy, suggesting that immunotherapy targeting PD-1/PD-L1 should take TILs into consideration [35]. Correlation analysis of our PDAC samples revealed that PD-L1 expression on ICs was significantly associated with high FOXP3\(^+\) T lymphocyte infiltration (\( p < 0.0001 \)). As PD-L1 functions in the induction and maintenance of T regulatory cells [36], the expression of PD-L1 and FOXP3 on stromal ICs could also be consistent. Similar to PD-L1, positive PD-L2 expression on TCs was associated with high FOXP3\(^+\) cells infiltration (\( p = 0.001 \)), which was consistent with the findings of a previous study [31].

Genomic instability, such as homologous recombination deficiency and MSI, could affect PD-1/PD-L1
immunotherapy in various tumours such as colon cancer, gastroesophageal cancer, and melanoma [21–23]. One study showed that BRCA1-deficient breast cancers were associated with increased PD-L1 expression in breast cancer [37]. In addition, Sato et al reported that BRCA2 depletion promotes PD-L1 upregulation in a Chk1-dependent manner in lung cancer, and prostate cancer cell lines and other signalling pathways, such as STAT1 and STAT3, are also required for double-strand break-dependent PD-L1 upregulation [38]. These results suggest that homologous recombination repair related proteins could regulate PD-1 ligand expression in tumours, and the regulation mechanisms are complex. However, the relationship between DDR molecules and PD-L1/PD-L2 in PDAC is not clear. In this study, we did not observe a correlation between PD-L1 and DDR molecules, whereas positive PD-L2 expression on TCs was associated with high BRCA2 expression ($p < 0.0001$). Based on previous studies, we hypothesised that, in PDAC, the regulation of homologous recombination repair associated proteins possibly occurs mainly in PD-L2. Nonetheless, the specific regulation mechanism needs to be investigated in future studies. Moreover, in the low BRCA1 expression group, positive PD-L2 expression on TCs was determined to be an independent risk indicator in terms of low DSS (HR: 1.523, 95% CI: 1.078–2.152, $p = 0.017$). Advanced PDAC patients with homologous recombination deficiency (usually caused by pathogenic BRCA mutations) harboured favourable outcomes based on poly ADP-ribose polymerase inhibitor (PARPi) treatment [39]; thus, combining PD-1 axis immunotherapy with PARPi chemotherapy may improve the prognosis of patients with both low BRCA and high PD-L2 expression.

A previous study reported that positive expression of PD-L1 is associated with p53 expression in oral squamous carcinoma [40]. Moreover, p53 could support the expression of JAK2 and thereby participate in IFN-$\gamma$-induced PD-L1 expression in melanoma cells [41]. These results suggest a correlation between p53 and PD-L1 in tumours; however, the correlation between p53 and PD-L2 in PDAC has not yet been reported. Our results showed no significant correlation between PD-L2 expression and p53 status. However, in the WT p53 group, positive PD-L2 expression on TCs was an independent risk factor (HR: 2.220, 95% CI: 1.061–4.647, $p = 0.034$) for a low DSS. Another crucial observation in this study was that PD-L2 expression on TCs was also related to a low DSS in the pMMR subgroup ($p = 0.004$). Accumulating evidence suggests that tumours with dMMR status can synthesise neoantigens and upregulate PD-L1 expression by enhancing the release of IFN-$\gamma$ from TILs [42,43]. Thus, PD-1/PD-L1 immunotherapy in MSI-positive tumours showed a high response. Here, our results showed that, even in patients with a normal p53 and pMMR status, PD-L2 could serve as a significant indicator of the survival potential of a patient, which may be useful for novel risk model construction and clinical treatment decision-making for PDAC.

Another interesting result in this study was that post-operative chemotherapy could benefit patients in terms of DSS in both PDL1-TC (-) and PDL1-TC (+) groups, while it only affected survival in patients who showed negative PD-L1 expression on ICs. A similar result was also observed for PD-L2. One previous study reported that silencing of the immune checkpoint B7-H3 could promote apoptosis and increase gemcitabine sensitivity in PDAC [44]. These results suggested that there was a potential correlation between immune checkpoint and chemotherapy efficacy.

Several limitations were noted in this study. First, considering the heterogeneity within tumours, TMA cores may not accurately represent the entire tumour. Second, it was difficult to assess PD-L1 and PD-L2 expression in different subgroups of ICs and analyse the co-expression of various lymphocyte markers and PD-L1/PD-L2 using immunohistochemistry. Future studies could be performed with multiplex IHC. Third, the mechanisms of the correlations between BRCA1, BRCA2, p53 status, MMR status, and PD-L2 were not explored in this study. However, despite these limitations, our study provides novel insights into the relationship between immune checkpoints and other gene signatures, which may contribute to the development of new combination therapy regimens and personalised treatment for PDAC.

**Conclusion**

This study determined that both PD-L1 and PD-L2 contribute to the prediction of PDAC prognosis. Unlike PD-L1, PD-L2 has been reported less frequently in PDAC. In this study, we determined that PD-L2 was associated with Treg cell infiltration and BRCA2 status. In addition, PD-L2 could be a potential biomarker for anti-PD-1 axis immunotherapy selection in patients with normal p53 and pMMR status. Our findings further refine our understanding of the PD-1 axis, providing a reference for personalised and precise treatment.
Acknowledgements

We thank Y. Junyi Pang for providing technical assistance. We would like to thank Editage (www.editage.cn) for English language editing.

This work was supported by grants from the Chinese Academy of Medical Sciences Initiative for Innovative Medicine (CAMS-2016-I2M-1-001), the National Natural Science Foundation of China (No. 81672648), and the National Scientific Data Sharing Platform for Population and Health (NCMI-YF01N-201906).

Author contributions statement

JC substantially contributed to the conceptualisation and design, and critical revising of the manuscript. XC, SM, HM, SY and ZL contributed substantially to analysis and interpretation of data and drafting the article. YZ provided substantial contributions to conceptualisation and design, analysis and interpretation of data, and drafting the article. All authors read and approved the final manuscript to be published.

Data availability statement

The data sets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.

References

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin 2018; 68: 7–30.
2. Luke JJ, Flaherty KT, Ribas A, et al. Targeted agents and immunotherapies: optimizing outcomes in melanoma. Nat Rev Clin Oncol 2017; 14: 463–482.
3. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 2015; 373: 1627–1639.
4. O’Reilly EM, Oh DY, Dhani N, et al. Durvalumab with or without tremelimumab for patients with metastatic pancreatic ductal adenocarcinoma: a phase 2 randomized clinical trial. JAMA Oncol 2019; 5: 1431–1438.
5. Schachter J, Ribas A, Long GV, et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet 2017; 390: 1853–1862.
6. Sharma P, Hu-Lieskovan S, Wargo JA, et al. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell 2017; 168: 707–723.
7. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366: 2443–2454.
8. Ishida Y, Agata Y, Shibahara K, et al. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 1992; 11: 3887–3895.
9. Iwai Y, Hamanishi J, Chamoto K, et al. Cancer immunotherapies targeting the PD-1 signaling pathway. J Biomed Sci 2017; 24: 26.
10. Keir ME, Butte MJ, Freeman GJ, et al. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008; 26: 677–704.
11. Yamazaki T, Akiba H, Iwai H, et al. Expression of programmed death 1 ligands by murine T cells and APC. J Immunol 2002; 169: 5538–5545.
12. Messal N, Serriari NE, Pastor S, et al. PD-L2 is expressed on activated human T cells and regulates their function. Mol Immunol 2011; 48: 2214–2219.
13. Lesterhuis WJ, Steer H, Lake RA. PD-L2 is predominantly expressed by Th2 cells. Mol Immunol 2011; 49: 1–3.
14. Yi M, Jiao D, Xu H, et al. Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors. Mol Cancer 2018; 17: 129.
15. Green MR, Monti S, Rodig SJ, et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood 2010; 116: 3268–3277.
16. Steidl C, Shah SP, Woolcock BW, et al. MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. Nature 2011; 471: 377–381.
17. Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2015; 372: 2018–2028.
18. Herbst RS, Soria JC, Kowanetz M, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014; 515: 563–567.
19. Yearley JH, Gibson C, Yu N, et al. PD-L2 expression in human tumors: relevance to anti-PD-1 therapy in cancer. Clin Cancer Res 2017; 23: 3158–3167.
20. Jackson SP, Bartek J. The DNA-damage response in human biology and disease. Nature 2009; 461: 1071–1078.
21. Jin Z, Yoon HH. The promise of PD-1 inhibitors in gastrointestinal cancers: microsatellite instability vs. PD-L1. J Gastrointest Oncol 2016; 7: 771–788.
22. Yaghoubi N, Soltani A, Ghazvini K, et al. PD-1/PD-L1 blockade as a novel treatment for colorectal cancer. Biomed Pharmacother 2019; 110: 312–318.
23. Hugo W, Zaretzky JM, Sun L, et al. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell 2016; 165: 35–44.
24. Williams AB, Schumacher B. p53 in the DNA-damage-repair process. Cold Spring Harb Perspect Med 2016; 6: a026070.
25. Danilova L, Ho WJ, Zhu Q, et al. Programmed cell death ligand-1 (PD-L1) and CD8 expression profiling identify an immunologic subtype of pancreatic ductal adenocarcinomas with favorable survival. Cancer Immunol Res 2019; 7: 886–895.
26. Oshima M, Okano K, Muraki S, et al. Immunohistochemically detected expression of 3 major genes (CDKN2A/p16, TP53, and
SMAD4/DPC4) strongly predicts survival in patients with resectable pancreatic cancer. *Ann Surg* 2013; 258: 336–346.

27. Beger C, Ramadani M, Meyer S, *et al.* Down-regulation of BRCA1 in chronic pancreatitis and sporadic pancreatic adenocarcinoma. *Clin Cancer Res* 2004; 10: 3780–3787.

28. Arnason T, Sapp HL, Rayson D, *et al.* Loss of expression of DNA mismatch repair proteins is rare in pancreatic and small intestinal neuroendocrine tumors. *Arch Pathol Lab Med* 2011; 135: 1539–1544.

29. Morton JP, Timpson P, Karim SA, *et al.* A PD-L2-based immune marker signature helps to predict survival in resected pancreatic ductal adenocarcinoma. *J Immunother Cancer* 2019; 7: 233.

30. Iwatate Y, Hoshino I, Yokota H, *et al.* Radiogenomics for predicting p53 status, PD-L1 expression, and prognosis with machine learning in pancreatic cancer. *Br J Cancer* 2020; 123: 1253–1261.

31. Zhang Y, Xu J, Hua J, *et al.* PD-L1 and PD-L2 on TCs in relation to DDR molecules of PDAC. *Oncol Lett* 2013; 5: 1779.

32. Orhan A, Vogelsang RP, Andersen MB, *et al.* The prognostic value of tumour-infiltrating lymphocytes in pancreatic cancer: a systematic review and meta-analysis. *Eur J Cancer* 2020; 132: 71–84.

33. Brunner M, Maier K, Rümmele P, *et al.* Upregulation of CD20 positive B-cells and B-cell aggregates in the tumor infiltration zone is associated with better survival of patients with pancreatic ductal adenocarcinoma. *Int J Mol Sci* 2020; 21: 1779.

34. Wang WQ, Liu L, Xu HX, *et al.* Infiltrating immune cells and gene mutations in pancreatic ductal adenocarcinoma. *Br J Surg* 2016; 103: 1189–1199.

35. Teng MW, Ngiow SF, Ribas A, *et al.* Classifying cancers based on T-cell infiltration and PD-L1. *Cancer Res* 2015; 75: 2139–2145.

36. Francisco LM, Salinas VH, Brown KE, *et al.* PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. *J Exp Med* 2009; 206: 3015–3029.

37. Wen WX, Leong CO. Association of BRCA1- and BRCA2-deficiency with mutation burden, expression of PD-L1/PD-1, immune infiltrates, and T cell-inflamed signature in breast cancer. *PLoS One* 2019; 14: e0215381.

38. Sato H, Niimi A, Yasuhara T, *et al.* DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells. *Nat Commun* 2017; 8: 1751.

39. Golan T, Hammel P. Management of BRCA mutation carriers with pancreatic adenocarcinoma. *J Natl Compr Canc Netw* 2021; 19: 469–473.

40. Ahmadi N, Gao K, Chia N, *et al.* Association of PD-L1 expression in oral squamous cell carcinoma with smoking, sex, and p53 expression. *Oral Surg Oral Med Oral Pathol Oral Radiol* 2019; 128: 631–638.

41. Thiem A, Hesbacher S, Kneitz H, *et al.* IFN-gamma-induced PD-L1 expression in melanoma depends on p53 expression. *J Exp Clin Cancer Res* 2019; 38: 397.

42. Xiao Y, Freeman GJ. The microsatellite instable subset of colorectal cancer is a particularly good candidate for checkpoint blockade immunotherapy. *Cancer Discov* 2015; 5: 16–18.

43. Gubin MM, Zhang X, Schuster H, *et al.* Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. *Nature* 2014; 515: 577–581.

44. Zhao X, Zhang GB, Gan WJ, *et al.* Silencing of B7-H3 increases gemcitabine sensitivity by promoting apoptosis in pancreatic carcinoma. *OncoLett* 2013; 5: 805–812.